Cornerstone Pharmaceuticals to Present at the BioNJ 7th Annual BioPartnering Conference, May 23, 2017

Cornerstone will present to investors and biopharmaceutical executives from around the Northeast region

Newark, New Jersey, UNITED STATES

Cranbury, NJ, May 22, 2017 (GLOBE NEWSWIRE) -- Information on Cornerstone's upcoming presentation at this prestigious industry conference provided below: 

WHAT:  In partnership with J.P. Morgan, the BioPartnering Conference is expected to bring together over 200 regional biopharmaceutical executives, investors, academic collaborators and business development professionals for a day of networking, 1-1 partnering meetings, company presentations, exhibits and plenary sessions. Sanjeev Luther, Cornerstone’s Chief Operating Officer, will present information on the Company’s novel Altered Energy Metabolism Directed (AEMD) platform, and will provide an update on Cornerstone’s clinical trial development strategy in the wake of the company’s recent announcement that it has received approval from the FDA to conduct pivotal clinical trials in acute myeloid leukemia and pancreatic cancer.

Interviews with Mr. Luther prior to and during the conference are available upon request.

WHERE: Busch Campus Center, Rutgers University; 604 Bartholomew Road – Piscataway, NJ 08854

WHEN: May 23, 2017, 1:45 PM

CONTACT: Jacob Jonas, 973-438-3716 or, for more information.     

About Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Cornerstone’s primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has given Cornerstone approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit